$IBRX

ImmunityBio stock surged 11.2% after Macau approved its bladder cancer drug Anktiva, marking the company's first Asian regulatory victory and potential gateway for regional expansion.

ImmunityBio stock rises 2.01% after NCCN includes Anktiva bladder cancer therapy in updated clinical guidelines; FDA resubmission underway.

ImmunityBio shares surge 10.6% after completing NK cell manufacturing programs producing five billion cells safely, plus FDA acknowledges ANKTIVA resubmission for bladder cancer.

Lucid Group tops the most-shorted stocks list as of March 11, 2026, highlighting investor skepticism toward struggling EV manufacturers amid broader market volatility.

ImmunityBio completed Phase 3 cancer trial enrollment ahead of schedule with strong 85% response rates. Anktiva sales surged 750% year-over-year, hitting $38.29M in revenue.

ImmunityBio launches 85-person European sales team for bladder cancer drug Anktiva across 30 countries, partnering with Accord Healthcare and establishing an Irish subsidiary for distribution.

ImmunityBio shares surged 41% after Europe approved its bladder cancer therapy ANKTIVA, enabling commercialization across 30+ nations and opening significant revenue opportunities.

Biotech firms advance treatment-resistant cancer therapies across multiple platforms, including oncolytic viruses and cellular immunotherapy, with several candidates achieving regulatory milestones and encouraging clinical data.

Short interest surges in hospitality and EV stocks as investors bet against overvalued companies. Choice Hotels, Lucid, and Avis lead with over 48% short positions.